Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
FDA Approves First CAR-T Therapy for Marginal Zone Lymphoma
Biotech & Bioprocessing FDA Approves First CAR-T Therapy for Marginal Zone Lymphoma

Imagine a landscape where a rare cancer, often resistant to repeated treatments, finally meets a game-changing solution. On December 4, this became reality as the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel, marketed as Breyanzi by Juno Therapeutics, as the first

Breakthrough Reveals How Cell Death Drives Dementia
Tech & Innovation Breakthrough Reveals How Cell Death Drives Dementia

For decades, the story of dementia has been told through the lens of the wreckage it leaves behind, focusing on the sticky protein plaques that litter the brains of patients. But what if the true villain is not the aftermath of the battle, but the very first shot fired—a preemptive act of cellular

Junevity's siRNA Platform Targets Metabolic Disorders
Biotech & Bioprocessing Junevity's siRNA Platform Targets Metabolic Disorders

Imagine a world where a single treatment could manage type 2 diabetes or obesity for months at a time, freeing patients from the burden of daily medications and the frustrating cycle of weight regain. This isn’t a distant dream but a potential reality being shaped by Junevity, a biotechnology

Rethinking Aging: Beyond Hallmarks and Current Measures
Research & Development Rethinking Aging: Beyond Hallmarks and Current Measures

Imagine a world where living to 100 is common, yet the decline of mind and body feels just as relentless as it does today—where longer life doesn’t mean slower aging. This paradox lies at the heart of a provocative critique by Dr. Dan Ehninger and Dr. Maryam Keshavarz, published in Genomic

Insitro Appoints Top Advisors to Advance AI Drug Discovery
Research & Development Insitro Appoints Top Advisors to Advance AI Drug Discovery

Imagine a world where the trial-and-error nature of drug discovery is replaced by a precise, predictive system capable of designing therapies for some of humanity’s most stubborn diseases. This vision is no longer a distant dream but a tangible goal for insitro, a South San Francisco-based AI

SAMP-Score Machine Learning – Review
Tech & Innovation SAMP-Score Machine Learning – Review

Imagine a world where the most stubborn cancers, those that defy conventional treatments, can be halted not by destroying cells but by coaxing them into a state of permanent rest. This vision is inching closer to reality with a pioneering technology that harnesses the power of machine learning to

TDP43's Dual Role in Neurodegeneration and Cancer Uncovered
Research & Development TDP43's Dual Role in Neurodegeneration and Cancer Uncovered

Diving into the intricate world of molecular biology and neurodegenerative disease research, I’m thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with a wealth of experience in research and development. His innovative work has pushed boundaries in understanding the complex

Cryo-Electron Microscopy in Epilepsy – Review
Research & Development Cryo-Electron Microscopy in Epilepsy – Review

Imagine a world where the intricate dance of molecules within the brain can be captured in stunning detail, offering a roadmap to tackle one of neurology’s most persistent challenges—epilepsy. This vision is becoming reality thanks to cryo-electron microscopy (Cryo-EM), a cutting-edge technology

How Does STREAMS Standardize Microbiome Research Globally?
Tech & Innovation How Does STREAMS Standardize Microbiome Research Globally?

Diving into the complex world of microbiome research, I had the privilege of speaking with Ivan Kairatov, a renowned biopharma expert with extensive experience in technology and innovation within the industry. With a strong background in research and development, Ivan has been instrumental in

What Is the Optimal ADT Duration With Prostate Radiation?
Research & Development What Is the Optimal ADT Duration With Prostate Radiation?

Ivan Kairatov has spent years at the crossroads of oncology and drug development, translating trial signals into day-to-day decisions for patients with localized prostate cancer. In this conversation, he unpacks new evidence showing that most of the value from androgen deprivation therapy (ADT)

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later